Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/9/2010

the Company's plan to focus its resources on the continued development of picoplatin, the Company's assessment of the value of the picoplatin asset and the commercial and therapeutic potential of picoplatin, the Company's plan to explore strategic alternatives to support the continued development of picoplatin, and the Company's goal of optimizing shareholder value. Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties inherent in the Company's business, including the Company's anticipated future operating losses, need for future capital and ability to obtain future funding on a timely basis, on favorable terms, or at all; the risk that strategic relationships may not be established on a timely basis, on terms that are ultimately favorable to the Company, or at all; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the Company's ability to retain key personnel; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation and general market conditions; the receipt and timing of FDA and other required regulatory approvals, if at all; the Company's ability to maintain compliance with Nasdaq listing standards; and other the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2009 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. Readers are cauti
'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014  CorMedix Inc. (NYSE MKT: ... commercializing therapeutic products for the prevention and treatment ... to announce that TUV-SUD and The Medicinal Evaluation ... (MEB) has granted its request for a label ... was initially approved in July 2013 for use ...
(Date:9/22/2014)... 2014 Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, announced ... appointed President and Chief Executive Officer, effective immediately.  Mr. Grossman ... down from his executive and Board roles but will ... first quarter of 2016.  Mr. Grossman ...
(Date:9/22/2014)... 2014 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced that its Board of Directors (the "Board") ... from Endo International plc ("Endo") and, after consulting ... unanimously determined it is not a superior proposal ... with QLT Inc. ("QLT") and has unanimously reaffirmed ...
Breaking Medicine Technology:Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
... 11, 2012  SuccessEHS announces that its newest release will ... when compared to previous releases.  The company has optimized ... (EHR) and Practice Management software solution ... upcoming release will focus on user efficiency and physician ...
... Jan. 11, 2012  nContact, Inc., the leading innovator ... recently launched corporate website, www.ncontactinc.com , has ... in Class Medical Site, presented by the nonprofit ... Studio 1440, has been recognized for excellence in ...
Cached Medicine Technology:Newest SuccessEHS Release to Increase Physician Software Usability 2Newest SuccessEHS Release to Increase Physician Software Usability 3nContact's Corporate Website Recognized as Best in Class Medical Site by Interactive Media Council - www.ncontactinc.com 2
(Date:9/22/2014)... 22, 2014 The Little Gym of ... Soles4Souls, a charitable organization based in Nashville, Tennessee that provides ... proper footwear. A pair of shoes can, seriously, change the ... on their feet. Confidence, comfort, and health are all improved ... of shoes to play, grown, and live. Aside from the ...
(Date:9/22/2014)... In a collaboration that will encompass a broad ... patient care and accelerate personalized genomic medicine, The ... Center (BIDMC) have established a new academic, research ... , A recently signed agreement calls for JAX ... comprehensive relationship in the areas of research and ...
(Date:9/22/2014)... 22, 2014 A team of doctors ... mesothelioma is better than ever thanks to ongoing improvements ... article on its website. Click here to read ... and the Massey Cancer Center analyzed the average survival ... type of mesothelioma that occurs in the abdominal lining. ...
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... course from Winter & Alvin has just been ... excitement throughout the personal development community. The media ... attention of HonestyFirstReviews.com's Tiffany Hendricks prompting an investigative ... topic of great interest for many entrepreneurs and ...
(Date:9/22/2014)... The professional review website, Best Cheap Hosting ... companies and announced that Certified Hosting ( http://www.best-cheap-hosting-usa.com/go/CertifiedHosting/ ... hosting suppliers for webmasters who want to buy ... hosting) at affordable rates. , The spokesman for ... our customers will find many other creative ways ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston and Stride Rite Partner to Support Soles4Souls 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 3Health News:Report Says New Treatments Have Dramatically Improved Outcomes for People with Peritoneal Mesothelioma, According to Surviving Mesothelioma 2Health News:"The Millionaire's Brain" - A Review Examining Winter & Alvin's Training Course Released 2
... James M. Farrell, a,doctor of chiropractic practicing in Golden, ... (CCA). He was nominated,and chosen by his fellow doctors ... since 1992, Dr. Farrell has been extremely active,with the ... chair, board member,and executive board member prior to his ...
... 2007 Today researchers report a newly identified ... prostate cancer in African American men. This study, ... with prostate cancer in high-risk populations, is published online ... Prostate cancer is the second leading cause of cancer ...
... scientists say , WEDNESDAY, Oct. 31 (HealthDay News) -- Scientists ... catus ), an advance they say will lead to health ... for human disease. , A four-year-old Abyssinian cat named Cinnamon, ... was the subject of the genome sequencing by scientists with ...
... WEDNESDAY, Oct. 31 (HealthDay News) -- Screening MRIs can uncover ... As a matter of fact, that might happen more than ... found that 7.2 percent of those who received MRIs had ... aneurysms, and 1.6 had benign brain tumors. , "Our study ...
... 31 The Medicare bidding,program for durable medical ... homecare infrastructure" unless Congress modifies,the program. This is ... a,congressional subcommittee today by the American Association for ... patients,standard of care, choice of provider, and access ...
... - Haemacure Corporation,(TSX:HAE), a specialty bio-therapeutics company, announces ... Rodman & Renshaw 9th Annual,Healthcare Conference, on November ... York,Palace Hotel in New York. Rodman & ... presentation and,post the associated slides via its website ...
Cached Medicine News:Health News:Golden Doctor of Chiropractic Elected President of the Colorado Chiropractic Association 2Health News:Scientists discover genetic variant associated with prostate cancer in African Americans 2Health News:Brain MRIs Find Hidden Neurological Problems 2Health News:Brain MRIs Find Hidden Neurological Problems 3Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 3Health News:Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec 2
... The ANA and ENA assays ... patients negative for antinuclear antibodies, which ... diseases such as Systemic lupus erythematosus ... disease, progressive systemic sclerosis, scleroderma, polymyositis, ...
... The ANA and ENA assays can ... negative for antinuclear antibodies, which are ... such as Systemic lupus erythematosus (Lupus), ... progressive systemic sclerosis, scleroderma, polymyositis, dermatomyositis, ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
... VerifyNow Clopidogrel Assay measures changes in ... taking Clopidogrel (Plavix). It uses a ... which clopidogrel inhibits. The assay has ... however, the assay is available for ...
Medicine Products: